share_log

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $45

Moomoo 24/7 ·  Mar 20 06:28

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $35 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment